Tyroserleutide TFA

Research use only, not for human use.

Tyroserleutide TFA, isolated from the degradation products of porcine spleen, is a small molecular tripeptide which inhibits tumor growth both in vitro and in vivo.

Tyroserleutide TFA, isolated from the degradation products of porcine spleen, is a small molecular tripeptide which inhibits tumor growth both in vitro and in vivo.(In Vitro):Tyroserleutide (YSL) exhibits immuno-modulating effects, such as enhancing concanavalin (ConA) induced proliferation of mouse spleen lymphocytes, phagocytosis of mouse peritoneal macrophages, and the activity of natural killer (NK) cells. Tyroserleutide (YSL), an immunologically therapeutic tripeptide, can promote hepatocarcinoma cell (H22) apoptosis through downregulating Bcl-2 and cyclin D1 expression. Tyroserleutide is an ideal choice for inducing apoptosis of liver tumor cells. Tyroserleutide inhibits tumor growth and does not cause severe toxicities in the major organs. Tyroserleutide can inhibit tumor cell migration.(In Vivo):Tyroserleutide (10-80 μg/kg; injection (i.p.) one time every day until mice are dead) displays obvious anti-tumor activity. Tyroserleutide significantly prolongs the survival time of the murine H22 implanted mice.

Others

Other Targets

Antitumor tripeptide

——

——

--

495.5

C20H28F3N3O8

>98% (HPLC)

——

——

(-20℃)

With Ice Pack

≥ 2 years